Blue Medical Devices
Translumina is a global leader in interventional cardiovascular devices, dedicated to advancing healthcare through innovative technology and clinical excellence. With manufacturing facilities in India, Germany, and the Netherlands, the company specializes in producing high-quality drug-eluting stents, balloons, and other cardiovascular solutions. Since its inception in 2010, Translumina has expanded its global presence, acquired other companies, and launched numerous innovative products, including the world's first polymer-free drug-eluting stent. The company emphasizes rigorous quality standards, clinical research, regulatory compliance, and strategic partnerships to improve patient outcomes worldwide. Its mission is to explore limitless possibilities for life by transforming patient care and medical technology.
Industries
Nr. of Employees
small (1-50)
Blue Medical Devices
Metro Tower, Plot 1, LSC Morland, Jagan Nath Madhok Marg, Pocket J, Part 2, New Rajinder Nagar, New Delhi, 110060 - India
Patents
Products
Drug-eluting stent systems (sirolimus / everolimus; polymer-free and biodegradable polymer variants)
Coronary stent platforms incorporating drug-delivery matrices (polymer-free formulations and biodegradable polymer coatings) developed for controlled local drug release and vascular healing.
Drug-coated balloon (DCB) technologies
Balloon catheters with drug-coated surfaces designed for homogeneous drug transfer to vessel walls without leaving an implanted matrix; includes coating methods and surface treatments to reduce drug loss and enable multiple inflations.
Coronary PTCA and non-compliant balloon catheters
PTCA balloon catheter products including non‑compliant designs with premoulded tip technology and twin-shaft configurations to improve pushability, kink resistance and tip strength for complex lesions.
Vascular access devices and catheter accessories
Accessory devices to support vascular access and interventional procedures, including peripheral and coronary accessories used during PCI and related interventions.
Drug-eluting stent systems (sirolimus / everolimus; polymer-free and biodegradable polymer variants)
Coronary stent platforms incorporating drug-delivery matrices (polymer-free formulations and biodegradable polymer coatings) developed for controlled local drug release and vascular healing.
Drug-coated balloon (DCB) technologies
Balloon catheters with drug-coated surfaces designed for homogeneous drug transfer to vessel walls without leaving an implanted matrix; includes coating methods and surface treatments to reduce drug loss and enable multiple inflations.
Coronary PTCA and non-compliant balloon catheters
PTCA balloon catheter products including non‑compliant designs with premoulded tip technology and twin-shaft configurations to improve pushability, kink resistance and tip strength for complex lesions.
Vascular access devices and catheter accessories
Accessory devices to support vascular access and interventional procedures, including peripheral and coronary accessories used during PCI and related interventions.
Services
End-to-end production services for stents, balloon catheters and drug-coating processes across multiple certified facilities.
Protocol development, site identification and management, monitoring, registry submissions and results dissemination for interventional cardiovascular studies.
Preparation and management of regulatory dossiers, product registrations and compliance activities for multiple regions and evolving regulatory frameworks.
In‑house mechanical, physiological and microbiological testing supporting product release, validation and stability studies under GLP practices.
Partnerships for joint development in biomedical engineering, materials science and device platforms, including translational work with clinical centers.
Workshops, webinars and training sessions for clinicians and partners focused on device use and procedural techniques.
End-to-end production services for stents, balloon catheters and drug-coating processes across multiple certified facilities.
Protocol development, site identification and management, monitoring, registry submissions and results dissemination for interventional cardiovascular studies.
Preparation and management of regulatory dossiers, product registrations and compliance activities for multiple regions and evolving regulatory frameworks.
In‑house mechanical, physiological and microbiological testing supporting product release, validation and stability studies under GLP practices.
Partnerships for joint development in biomedical engineering, materials science and device platforms, including translational work with clinical centers.
Workshops, webinars and training sessions for clinicians and partners focused on device use and procedural techniques.
Expertise Areas
- Interventional cardiovascular device manufacturing
- Drug-eluting stent development and clinical evaluation
- Drug-coated balloon development and evaluation
- Clinical trial management and registry operations
Key Technologies
- Drug-eluting stent platforms (sirolimus/everolimus; polymer-free and biodegradable polymer approaches)
- Drug-coated balloon (DCB) technologies
- PVP-based drug carrier coatings
- Micro-porous surface coatings for controlled release
News & Updates
Translumina, a global leader in Interventional Cardiovascular medical devices with manufacturing presence in Germany and India, today announced the acquisition of Blue Medical Devices, a Wellinq group company, based out of Helmond, Netherlands.
World’s 1st company to have 2 Drug Eluting Stent technologies with 10 years clinical safety and efficacy data
Translumina has developed two drug-eluting stent technologies with a decade of clinical safety and efficacy data, demonstrating its leadership in cardiovascular device innovation.
Translumina, a global leader in Interventional Cardiovascular medical devices with manufacturing presence in Germany and India, today announced the acquisition of Blue Medical Devices, a Wellinq group company, based out of Helmond, Netherlands.
World’s 1st company to have 2 Drug Eluting Stent technologies with 10 years clinical safety and efficacy data
Translumina has developed two drug-eluting stent technologies with a decade of clinical safety and efficacy data, demonstrating its leadership in cardiovascular device innovation.